Medical Center New Polyclinic Gabrovo Ltd.

Gabrovo 13 trials 4 recruiting

13 Registered trials

4 Currently recruiting

Organisation

Medical Center New Polyclinic Gabrovo Ltd.

Location

Gabrovo, Bulgaria

Identifier

ORG-100046048

Address

Mogilev 52a, 5300, Bulgaria

Departments

-
#2209
#3003
Cardiology cabinet
Medical Center
N/A
NA
Office of Endocrinology and metabolic diseases

Clinical trials at this site (13)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio… Recruiting

2024-519525-38-00 Heart failure 5 2025-08-22
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu… Recruiting

2023-506460-14-00 Chronic kidney disease (CKD) and hypertension. 5 2025-05-07
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Ended

2025-523974-18-00 Obesity 5 2026-04-30
A Phase 3 Study to Assess the Safety and Immunogenicity of High-dose Influenza Vaccine in Adults ≥ 60 years of Age Ended

2024-519743-15-00 Influenza immunisation 5 2025-10-20
MLS-101-901: An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, and Tolerability of Lorundrostat in Subjects with Hyper… Ended

2023-508670-28-00 Hypertension 5 2024-08-26
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejec… Ended

2023-508736-62-00 Heart failure (HF) with reduced ejection fraction (HFrE 4 2024-08-08
A Phase 2 Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejecti… Ended

2023-508737-13-00 chronic heart failure 4 2024-08-08
MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended

2023-506425-12-00 Uncontrolled and Resistant Hypertension 5 2024-04-17
A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended

2023-504678-39-00 Heart Failure 4 2024-03-13